Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 22,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $50.01, for a total transaction of $1,100,220.00. Following the sale, the chairman now owns 58,014 shares of the company’s stock, valued at approximately $2,901,280.14. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ionis Pharmaceuticals Inc (IONS) opened at $53.22 on Friday. The company has a market cap of $6,635.38, a PE ratio of 354.82 and a beta of 2.86. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals Inc has a fifty-two week low of $37.26 and a fifty-two week high of $65.51.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its holdings in Ionis Pharmaceuticals by 21.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after purchasing an additional 3,538 shares during the last quarter. Rothschild Asset Management Inc. grew its position in shares of Ionis Pharmaceuticals by 10.8% during the 3rd quarter. Rothschild Asset Management Inc. now owns 281,068 shares of the company’s stock worth $14,250,000 after buying an additional 27,426 shares during the period. Bank of Nova Scotia acquired a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $1,526,000. 361 Capital LLC acquired a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $1,596,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $1,096,000. Institutional investors and hedge funds own 91.40% of the company’s stock.
IONS has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. Morgan Stanley upped their price target on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 8th. Barclays cut their price objective on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a research report on Thursday, September 21st. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $50.76.
TRADEMARK VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/ionis-pharmaceuticals-inc-ions-chairman-stanley-t-crooke-sells-22000-shares.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.